Cablevision’s support of The Lustgarten Foundation ensures that 100% of every donation goes directly to pancreatic cancer research.


Research Awards Listing

Research follows dollars, and The Lustgarten Foundation believes that increasing funds for pancreatic cancer research will translate into enhanced patient care, and ultimately, a cure.

The Lustgarten Foundation firmly believes that increasing funds for pancreatic cancer research is the surest path to improved patient care and eventually, to a cure. To date, we have committed nearly $90 million to providing the best and brightest minds with the resources to pursue the study and eradication of the disease.

2013 Research Grants 

Analysis Targeting RAS Downstream Signaling with Combination Therapy Using a CDK5 Inhibitor with an AKT Inhibitor in Metastatic Pancreatic Cancer
Nilofar Azad, M.D. - Johns Hopkins University School of Medicine 

Targeting CCR2 to Overcome Immunosuppression and Improve Immunotherapy
David Denardo, Ph.D. – Washington University

Targeting of K-Ras Pathways with Small Molecules
Stephen Fesik, Ph.D. - Vanderbilt University

Targeting Desmoplasia to Improve Drug Delivery and Enhance Treatment of Pancreatic Ductal Adenocarcinoma
Rakesh Jain, Ph.D. - Massachusetts General Hospital 
Robert Langer, M.D. - Massachusetts Institute of Technology

Exploring the Functional Connection between Stromal Myofibroblasts and Tumor Immunity in PDAC to Unravel New Therapy Targets
Raghu Kalluri, M.D., Ph.D. - MD Anderson Cancer Center 

A Registry of BRCA Mutation Carriers with Pancreatic Ductal Adenocarcinoma
David Kelsen, M.D. - Memorial Sloan Kettering Cancer Center

Stand Up to Cancer Dream Team Convergence Research Grant
Elizabeth Jaffee, M.D. - Johns Hopkins University School of Medicine
Robert Vonderheide, M.D. – University of Pennsylvania

Rapid in Situ Generation of Pancreatic Tumor-Specific T Cells Using DNA Nanocarriers
Matthias Stephan, M.D., Ph.D. - Fred Hutchinson Cancer Research Center
In Vivo Analysis of Vitamin D-receptor Agonist as Cancer Therapy Modulator in Kras/p53-Dependent Murine Model of Pancreatic Ductal Adenocarcinoma
Terry Van Dyke, Ph.D. - The National Cancer Institute
Ronald Evans, Ph.D. – Salk Institute

Targeting Ras Using Cell-Penetrating Mini-Proteins
Greg Verdine, Ph.D. – Harvard University
Exosomes as a Diagnostic and Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma (PDAC)
Ralph Weissleder, M.D., Ph.D. - Massachusetts General Hospital
Experimental Surgical Clinical Trial for Pancreatic Cancer
Ken Yu, M.D. - Memorial Sloan Kettering Cancer Center
David Tuveson, M.D., Ph.D. - Cold Spring Harbor Laboratory

Elizabeth Jaffee, M.D., Johns Hopkins Medical Institutions
“As a result of Lustgarten Foundation funding, we were able to produce enough vaccine to test our potential therapy in pancreatic cancer patients. Without this funding, we would not have been able to conduct this trial.”
-  Elizabeth Jaffee, M.D., Johns Hopkins Medical Institutions

Lustgarten Foundation funds pancreatic cancer research through Bridge Project.

The Lustgarten Foundation has made a generous gift of $650,000 to the Bridge Project, an unparalleled collaboration between Dana-Farber/Harvard Cancer Center (DF/HCC) and the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT). (see page 6)

Join Now

Lustgarten Facebook Lustgarten Twitter Lustgarten YouTube channel

The Lustgarten Foundation
1111 Stewart Avenue, Bethpage, New York 11714
Toll Free: 1-866-789-1000 P: 516-803-2304 F: 516-803-2303

©2009 Lustgarten Foundation - 501(c)3 - CharityNavigator: 4 Stars